Sanofi falls after Q2 profit misses despite sales beat on higher costs

Published 31/07/2025, 09:46
© Reuters.

Investing.com -- Sanofi (EPA:SASY) shares fell more than 2% on Thursday after the pharmaceutical and healthcare company reported second-quarter profit that came in below expectations, even as sales topped forecasts, with rising operating expenses weighing on margins.

The French company posted business earnings per share of €1.59, missing the €1.65 consensus estimate. Business operating income declined 2% year over year to €2.46 billion, below the €2.58 billion analyst forecast.

Revenue rose 6% to €9.99 billion, beating the €9.79 billion average estimate. Growth was driven by Dupixent, Altuviiio, and vaccines including Beyfortus. 

Dupixent sales rose 16% to €3.83 billion, 2% above consensus, despite some pressure in China from the national reimbursement drug list renewal. Altuviiio reported 84% growth to €291 million, coming in 16% ahead of expectations.

Vaccine sales increased 6% to €1.21 billion, 5% above forecast, lifted by a sharp rise in Beyfortus revenue and late-season influenza vaccine demand. 

Beyfortus sales reached €72 million, up from €18 million a year earlier. Flu vaccines brought in €141 million, a 23% increase.

Total (EPA:TTEF) revenue was €10.74 billion, up from €10.16 billion a year earlier. Adjusted gross profit rose 8% to €7.74 billion, with gross margin improving to 77.5% from 76%.

R&D expenses increased 15% to €1.91 billion. Selling and general costs rose 4% to €2.28 billion. 

Other operating income grew 37% to €1.12 billion, driven in part by profit-sharing payments to Regeneron (NASDAQ:REGN) from the monoclonal antibody partnership. Business net income fell 1% to €1.94 billion.

Sanofi raised its full-year sales growth guidance to high single digits at constant exchange rates, up from a prior mid-to-high single-digit range.

However, it flagged a larger foreign exchange impact of -4%, which implies full-year sales between €41.6 billion and €43.2 billion, below the consensus forecast of €43.6 billion.

The company now expects business EPS between €7.56 and €7.70 for 2025, based on a 6% FX impact and including costs from newly acquired businesses. 

The consensus estimate stands at €7.97. Sanofi said its effective tax rate remains broadly stable, with 2024 at 19.8%, in line with the 19.9% consensus.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.